Recent advances in AML with mutated NPM1.
Ishikawa Y, Ushijima Y, Kiyoi H.
Int J Hematol. 2024 Nov;120(5):556-565. doi: 10.1007/s12185-024-03835-8. Epub 2024 Aug 22.
NPM1-mutated acute myeloid leukemia: from bench to bedside.
Falini B, Brunetti L, Sportoletti P, Martelli MP.
Blood. 2020 Oct 8;136(15):1707-1721. doi: 10.1182/blood.2019004226.
Significance of NPM1 Gene Mutations in AML.
Hindley A, Catherwood MA, McMullin MF, Mills KI.
Int J Mol Sci. 2021 Sep 17;22(18):10040. doi: 10.3390/ijms221810040.
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N.
Blood Adv. 2023 Mar 28;7(6):933-942. doi: 10.1182/bloodadvances.2022008316.
NPM1-mutated AML: how many diseases?
Itzykson R.
Blood. 2024 Aug 15;144(7):681-683. doi: 10.1182/blood.2024025032.
Minimal Residual Disease in NPM1-Mutated AML.
Burke MJ.
N Engl J Med. 2016 Feb 4;374(5):481-2. doi: 10.1056/NEJMe1515525. Epub 2016 Jan 20.
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.
Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.
Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.
Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies.
Nong T, Mehra S, Taylor J.
Cells. 2024 Aug 21;13(16):1392. doi: 10.3390/cells13161392.
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL.
N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14.
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri F, Nasillo V, Paolini A, Bettelli F, Pioli V, Giusti D, Gilioli A, Colasante C, Acquaviva G, Riva G, Barozzi P, Maffei R, Potenza L, Marasca R, Fozza C, Tagliafico E, Trenti T, Comoli P, Longo G, Luppi M.
Int J Mol Sci. 2020 Nov 26;21(23):8975. doi: 10.3390/ijms21238975.
